Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Multinational Double-Blind Placebo-Controlled Parallel-Group Design Pilot Study to Estimate the Tolerability, Safety, PK [pharmacokinetic] and PD [pharmacodynamic] Effects of Teriflunomide for 24 Weeks When Added to Interferon-beta in Subjects With Multiple Sclerosis.

Trial Profile

Randomized Multinational Double-Blind Placebo-Controlled Parallel-Group Design Pilot Study to Estimate the Tolerability, Safety, PK [pharmacokinetic] and PD [pharmacodynamic] Effects of Teriflunomide for 24 Weeks When Added to Interferon-beta in Subjects With Multiple Sclerosis.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Teriflunomide (Primary) ; Interferon beta; Interferon beta
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Sponsors Sanofi
  • Most Recent Events

    • 05 Jun 2010 One-year data from this study were the subject of the leading oral presentation at the American Committee for Treatment and Research in Multiple Sclerosis meeting (ACTRIMS) 2010, according to a sanofi-aventis media release.
    • 11 Sep 2009 Results were presented at ECTRIMS 2009.
    • 11 Sep 2009 Results were presented at ECTRIMS 2009, according to a sanofi-aventis media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top